Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

Buske C; Dreyling M; Alvarez-Larrán A; Apperley J; Arcaini L; Besson C; Bullinger L; Corradini P; Giovanni Della Porta M; Dimopoulos M; D'Sa S; Eich HT; Foà R; Ghia P; da Silva MG; Gribben J; Hajek R; Harrison C; Heuser M; Kiesewetter B; Kiladjian JJ; Kröger N; Moreau P; Passweg JR; Peyvandi F; Rea D; Ribera JM; Robak T; San-Miguel JF; Santini V; Sanz G; Sonneveld P; von Lilienfeld-Toal M; Wendtner C; Pentheroudakis G; Passamonti F.


Background: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group.Methods: This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance.Results and conclusion: The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.

Obre a Pubmed